Sun Pharmaceutical Industries has received approval from US Court to launch LEQSELVI, a drug used to treat autoimmune disorder that causes patchy hair loss, in the US. US court has ruled in its favour and vacated a preliminary injunction effective immediately removing restrictions on it launching LEQSELVI. The company has been locked in a patent infringement litigation with Incyte Corporation over LEQSELVI (deuruxolitinib).
On April 9, 2025, the US Court of Appeals for the Federal Circuit held an oral argument on the company's appeal of the US District Court for the District of New Jersey's decision that previously granted a preliminary injunction delaying the Company's launch of LEQSELVI in the US. Shortly after the oral argument concluded, the US Court of Appeals for the Federal Circuit ruled in favour of the company and vacated the preliminary injunction effective immediately.
While the litigation between Incyte Corporation and the company continues, the preliminary injunction is no longer in effect. The company is no longer under a court order that delays or restricts the company from launching LEQSELVI. The company will disclose LEQSELVI launch plans in due course of time.
Sun Pharmaceutical Industries is among the largest specialty generic pharmaceutical company and India's top pharmaceutical company.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1874.70 |
| Dr. Reddys Lab | 1285.60 |
| Cipla | 1335.00 |
| Zydus Lifesciences | 938.25 |
| Lupin | 2250.60 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: